Hemab Therapeutics Holdings, Inc. — Form 8-K
Filed August 11, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Hemab completed an IPO in May 2026 raising $317.2M net proceeds, bringing total cash to $457.5M (260% of total assets of $175.3M). The company advanced three clinical programs: sutacimig (Phase 3 initiation planned H2 2026 for Glanzmann thrombasthenia with FDA endorsement), HMB-002 (demonstrated ≥2.4-fold VWF/FVIII increase in Phase 1/2), and unveiled HMB-003 (novel plasmin inhibitor for heavy menstrual bleeding, first-in-human studies planned H2 2026). Q2 2026 R&D expenses were $20.3M (vs. $12.9M prior year); net loss was $24.2M ($0.80/share on 30.1M shares) for the quarter.
Why this rating
IPO capital influx is highly material—$317M proceeds fund operations into 2029. Three clinical programs with FDA support represent real near-term catalysts. Meaningful relative to $175M asset base, though success depends on trial outcomes.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.